Odyssey Therapeutics, led by Gary Glick, has officially entered the public markets, marking a significant milestone for the Boston-based biotechnology company. The move comes after the company postponed its initial public offering (IPO) plans last year. With this IPO, Odyssey Therapeutics becomes the latest in a series of biotech firms in the region to go…
